Dapivirine + Levonorgestrel Extended-Release Monthly Film
DPV + LNG Monthly Film
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Vaginal Gel
-
Intended Duration:
- Short-Acting
- Development Stage: Discovery & Early Development
- Developer(s)/researcher(s): Magee-Women's Research Institute, University of Pittsburgh
Details
- API: Dapivirine, Levonorgestrel
- Target: Progesterone Receptor
-
Mechanism of Action:
- Endometrial Changes
- Cervical Mucus Changes
- Inhibition of Sperm Motility
- Ovulation Inhibition
- Anti-Microbial
- Inactive Materials: Polyethylene Glycol, Hydroxypropyl Methyl Cellulose, Polyvinyl Alcohol
- Regimen: 1 Film/Month
- MPT: Potential MPT
- Promising Attributes: The method offers both pregnancy prevention and HIV prevention. This film is conjectured to be affordable, portable, and discreet.
Product Status
Recent Early Research. Development was supported through MATRIX, a terminated HIV prevention R&D program funded by USAID. Record will be monitored to determine if development will continue with new funding.
History
In 2020, a proof-of-concept study was published that demonstrated the ability of this novel bioadhesive film platform to deliver LNG and DPV simultaneously as an MPT product.